Selected Perspectives

Excellent execution does not mean the right problem is being solved. Drug development organizations are very good at solving difficult problems. They can design sophisticated trials, generate enormous amounts of data, manage increasingly complex global operations, and bring extraordinary scientific and technical expertise to bear on a development program. But excellent execution does not necessarily mean the right problem is being solved. And in drug development, solving the ...

Healthcare investors who underweight clinical execution risk do not just miss upside. They inherit the downstream consequences of assumptions made too early. Private equity and venture capital now shape significant portions of healthcare innovation, from therapeutics and diagnostics to AI-enabled care delivery and digital infrastructure. Yet one of the most consequential variables in healthcare investment remains consistently underpriced: clinical execution risk. The issue is not ...

Effective translational strategy reduces downstream failure by aligning science, endpoints, and execution from the start.

Most healthcare failures are not scientific; they result from underestimating clinical execution risk early.

Technical performance does not translate into impact without workflow alignment, evidence credibility, and governance.

Fractional leadership creates value only when it brings true decision authority, not advisory noise.

In crowded markets, the quality and credibility of evidence, not novelty, determines adoption and value.